Markets | | |
By now you know that on August 14, the United States bond market saw the yield on 2-year Treasury notes climb above the yield on 10-year Treasury notes. The “2-10 spread” is a significant marker for analysts. An inversion in this spread has occurred in advance of the last nine recessio... Read the Full Story |
|
From Our PartnersJoin a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week. | | Click Here to Download the FREE Report |
|
Stocks | | |
On a recent weekend trip, I was made aware that the future was closer to reality than I thought. While walking through the city, I did a double-take when my son said, “Dad, why does my phone say 5G?”
I took out my phone and there it was in the upper left-hand corner of my screen... Read the Full Story |
|
Markets | | |
When you invest your money, knowledge is power. So, before making an investment in a company, you should always perform a fundamental analysis to evaluate a company's intrinsic value. When examining the company’s financial and economic data, make sure you understand its cash flow.
Much like... Read the Full Story |
|
The Early Bird Stock Of The Day Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland. | | View Today's Stock Pick |
|
